Discovery of orally efficacious ROR gamma t inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.
Shirai, J., Tomata, Y., Kono, M., Ochida, A., Fukase, Y., Sato, A., Masada, S., Kawamoto, T., Yonemori, K., Koyama, R., Nakagawa, H., Nakayama, M., Uga, K., Shibata, A., Koga, K., Okui, T., Shirasaki, M., Skene, R., Sang, B., Hoffman, I., Lane, W., Fujitani, Y., Yamasaki, M., Yamamoto, S.(2018) Bioorg Med Chem 26: 483-500
- PubMed: 29262987
- DOI: https://doi.org/10.1016/j.bmc.2017.12.006
- Primary Citation of Related Structures:
6B30 - PubMed Abstract:
A series of novel phenylglycinamides as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists were discovered through optimization of a high-throughput screen hit 1. (R)-N-(2-((3,5-Difluoro-4-(trimethylsilyl)phenyl) amino)-1-(4-methoxyphenyl)-2-oxoethyl)-3-hydroxy-N-methylisoxazole-5-carboxamide (22) was identified as one of the best of these compounds. It displayed higher subtype selectivity and specificity over other nuclear receptors and demonstrated in vivo potency to suppress the transcriptional activity of RORγt in a mouse PD (pharmacodynamic) model upon oral administration.
Organizational Affiliation:
Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: junya.shirai@cardurion.com.